Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33372646

about

Early experience with novel immunomodulators for cancer treatment Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer Toll-like receptor agonists in cancer therapy.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.FimH can directly activate human and murine natural killer cells via TLR4 In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study Mantle cell lymphoma activation enhances bortezomib sensitivity.Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Development of TLR9 agonists for cancer therapy Human papillomavirus therapeutic vaccines in head and neck tumors.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.New adjuvants: EU regulatory developments.Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.Twelve immunotherapy drugs that could cure cancers.In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice.DNA vaccines for the treatment of prostate cancer.Cancer immunotherapy and nanomedicine.Toll-like receptor signaling pathways--therapeutic opportunities.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.

P2860

Q28241744-D92E4770-3B1C-45A5-8E35-2E205ED123D7 Q33388795-C44C43F3-83D1-4CE3-B967-B9EA67239B96 Q33792003-7676E510-18EA-43EE-90D4-1FC9845A99B8 Q33918509-485A79D8-1FC9-43DE-855A-0E3E6A21383E Q33960866-038615AC-5E73-4FCE-A7CC-4EA8EA2A9FD2 Q34025104-00845520-0980-4D35-8C1E-DD86A0273197 Q34194680-E08B6C09-AF2C-4665-8AC1-09FB42231A0A Q34360347-D1F2FF52-C196-4010-90E7-F5F732A6096B Q34618829-00543B57-70D2-4362-8114-DA9402FA948E Q34619324-86871166-3131-4082-84DB-72812D080B41 Q34757847-7BA525D9-0E3E-47C4-B130-07099EA161D5 Q35018021-24E188C9-4082-4249-84CF-A384B2538C54 Q35058213-E30EF20C-B8A4-4D01-B64A-9BAEEED64F7A Q35204579-1AA6A54B-52D1-4F84-AB60-57D816994B93 Q36092885-939D46B1-022A-4800-955E-4878FE106CFA Q36107932-00666DC9-62A0-46B1-8FEE-8384C98CC554 Q36194849-2E976EE7-E72D-49A1-9764-9444B6D74A55 Q36222910-4ABB814A-156F-4397-9ED5-DBCA05EA9B11 Q36403509-659D2BDF-4A37-4977-BE2B-C38230779818 Q36608597-802193A7-2751-459B-BA9F-A41A535B0CF2 Q36809776-CC64F9EA-9256-48C2-A7F1-D951F069AD7B Q36817148-74F302FD-732A-411D-B0AF-BAB52553858D Q36827406-5348CC54-BB88-4DEE-813A-E7EFEBEE04B8 Q36909391-15690405-5338-4979-829C-C6F75448808A Q36968305-5BD36CD4-6F29-41C2-A50D-FB9D6D6D0C67 Q37050998-90B77BF6-8C97-4685-BDAE-F66932C366E2 Q37051022-A7AB115F-0CB0-4C34-83CF-F41FA84AFC7D Q37118201-86DB6715-12C7-4180-94E5-14CEC9742E80 Q37220754-7154A70E-D9A2-4F04-93E5-2A73F394F081 Q37322304-EFFCAEB5-3871-470F-BE1C-59C93524524D Q37354301-7C572AEE-25BE-4CAF-BF39-35E2C66CFC0B Q37640319-221DF1F3-6E90-44B7-8FB7-C5A3E02DB73C Q37671216-64DAF9E2-E956-41C9-8E07-95ABDFCD43C1 Q37700490-D789A66F-5FF3-489B-8DA6-42A8DEC85A2F Q37771942-F4EEF16D-9D00-44BC-BB49-11756014ED94 Q37785836-F28F50DA-A422-4EFC-B54D-96899979C0DF Q37803540-3D4DAF2E-AD78-4C07-A15B-32B1A42A6F55 Q37832694-4EC7710A-F8A8-4AA7-B1B1-1FB41171E443 Q37940343-AB636D74-DAA0-4CF1-963A-6D0521D3DAEF Q38131836-7545569A-1DB7-424D-A044-9F09EBEFE177

P2860

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33372646

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@ast

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@en

type

label

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@ast

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@en

prefLabel

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@ast

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@en

P1433

Q33372646-9401E51D-BC8B-4424-AB9A-5759E63D94AE

P1476

Q33372646-77891A82-F161-484F-A38C-12B743257C96

P2093

Q33372646-0A0D7FD6-E67E-436C-AA4D-77717D80D38D

Q33372646-20A0B8DE-BB6C-4097-A2E0-8FD3CFF8C069

Q33372646-50D05093-AC50-4791-8F67-A992D0916765

Q33372646-646C4611-43CE-40B0-92A6-E3628A45F8AE

Q33372646-6943E094-EECF-4875-9F54-A1BC4682CC57

Q33372646-7C321D2F-2E79-498A-92A3-0BCD16A96C08

Q33372646-9A6400FF-0068-4D8E-BAC4-43B2831A7087

Q33372646-F11DF9FD-3C6A-4FC4-B476-E17389026916

P304

Q33372646-B5774B23-A54E-4B8C-A1D9-CF0F8B7705A1

P31

Q33372646-905F8D14-C96B-4570-9598-34A6A2935435

P356

Q33372646-1654F206-7017-490A-92CB-F9AF828EF2F1

P433

Q33372646-FEAB8E6F-EA6A-4763-B701-128969AD7ADC

P478

Q33372646-FEECA0BC-DB5F-4EE3-9D5C-A3E885D15446

P50

Q33372646-70943A52-D8E7-40AA-B82E-348A801F4650

P577

Q33372646-04AA359A-A4D1-4AEF-AC7A-8D28A4E7A8A7

P5875

Q33372646-26CA8361-EE76-425C-AD86-0BE0480F8930

P698

Q33372646-875B420F-5907-4186-97CF-0C90EFEE6631

P356

01.CJI.0000211304.60126.8F

P1433

Journal of Immunotherapy

P1476

Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.

@en

P2093

Aaron D Bossler

http://www.w3.org/2001/XMLSchema#string

Arthur M Krieg

http://www.w3.org/2001/XMLSchema#string

Brian K Link

http://www.w3.org/2001/XMLSchema#string

Daniel Weisdorf

http://www.w3.org/2001/XMLSchema#string

George J Weiner

http://www.w3.org/2001/XMLSchema#string

James E Wooldridge

http://www.w3.org/2001/XMLSchema#string

Mary Shannon

http://www.w3.org/2001/XMLSchema#string

Wendy L Rasmussen

http://www.w3.org/2001/XMLSchema#string

P304

558-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CJI.0000211304.60126.8F

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Zuhair K Ballas

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6818869

http://www.w3.org/2001/XMLSchema#string

P698

16971811

http://www.w3.org/2001/XMLSchema#string